APTO•benzinga•
Aptose Announces Cohort Safety Review Committee Monitoring Phase 1/2 TUSCANY Trial Of TUS+VEN+AZA Unanimously Approved Escalating From 40 mg TUS To 80 mg TUS
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 20, 2025 by benzinga